Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma

@inproceedings{Brouzas2009BevacizumabF,
  title={Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma},
  author={Dimitrios Brouzas and Antonios Charakidas and Marilita M Moschos and Chryssanthi N Koutsandrea and Michael N Apostolopoulos and Stefanos Baltatzis},
  booktitle={Clinical ophthalmology},
  year={2009}
}
PURPOSE To establish the efficacy and safety of intravitreal bevacizumab in reducing iris and anterior chamber angle neovascularization and managing neovascular glaucoma. DESIGN Prospective interventional case series. PATIENT AND METHODS Eleven eyes of 11 patients with iris and anterior chamber angle neovascularization with refractory intraocular pressure were treated with intravitreal injection of 1.25 mg bevacizumab (Avastin((R))). The study group included eight males and three females… CONTINUE READING